Clonal hematopoiesis with <i>DNMT3A</i> and <i>PPM1D</i> mutations impairs regeneration in autologous stem cell transplant recipients
Patrick Stelmach,
Sarah Richter,
Sandra Sauer,
Margarete A. Fabre,
Muxin Gu,
Christian Rohde,
Maike Janssen,
Nora Liebers,
Rumyana Proynova,
Niels Weinhold,
Marc S. Raab,
Hartmut Goldschmidt,
Birgit Besenbeck,
Petra Pavel,
Sascha Laier,
Andreas Trumpp,
Sascha Dietrich,
George S. Vassiliou,
Carsten Müller-Tidow
Affiliations
Patrick Stelmach
Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany; Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZZMBH Alliance, Heidelberg, Germany; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM, gGmbH), Heidelberg
Sarah Richter
Department of Medicine V, Heidelberg University Hospital, Heidelberg
Sandra Sauer
Department of Medicine V, Heidelberg University Hospital, Heidelberg
Margarete A. Fabre
Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK; Department of Haematology, University of Cambridge, Cambridge, UK; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, UK; Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R/D, AstraZeneca, Cambridge
Muxin Gu
Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK; Department of Haematology, University of Cambridge, Cambridge, UK; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge
Christian Rohde
Department of Medicine V, Heidelberg University Hospital, Heidelberg
Maike Janssen
Department of Medicine V, Heidelberg University Hospital, Heidelberg
Nora Liebers
Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany; National Center for Tumor Diseases (NCT), Heidelberg
Rumyana Proynova
Department of Medicine V, Heidelberg University Hospital, Heidelberg
Niels Weinhold
Department of Medicine V, Heidelberg University Hospital, Heidelberg
Marc S. Raab
Department of Medicine V, Heidelberg University Hospital, Heidelberg
Hartmut Goldschmidt
Department of Medicine V, Heidelberg University Hospital, Heidelberg
Birgit Besenbeck
Department of Medicine V, Heidelberg University Hospital, Heidelberg
Petra Pavel
Stem Cell Laboratory, Institute of Clinical Transfusion Medicine and Cell Therapy Heidelberg GmbH, Heidelberg
Sascha Laier
Stem Cell Laboratory, Institute of Clinical Transfusion Medicine and Cell Therapy Heidelberg GmbH, Heidelberg
Andreas Trumpp
Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZZMBH Alliance, Heidelberg, Germany; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM, gGmbH), Heidelberg, Germany; Faculty of Biosciences, Heidelberg University, Heidelberg, Germany; German Cancer Consortium (DKTK), Heidelberg
Sascha Dietrich
Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany; Molecular Medicine Partnership Unit, European Molecular Biology Laboratory (EMBL), Heidelberg
George S. Vassiliou
Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK; Department of Haematology, University of Cambridge, Cambridge, UK; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge
Carsten Müller-Tidow
Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany; National Center for Tumor Diseases (NCT), Heidelberg, Germany; Molecular Medicine Partnership Unit, European Molecular Biology Laboratory (EMBL), Heidelberg
Clonal hematopoiesis (CH) is an age-related condition driven by stem and progenitor cells harboring recurrent mutations linked to myeloid neoplasms. Currently, potential effects on hematopoiesis, stem cell function and regenerative potential under stress conditions are unknown. We performed targeted DNA sequencing of 457 hematopoietic stem cell grafts collected for autologous stem cell transplantation (ASCT) in myeloma patients and correlated our findings with high-dimensional longitudinal clinical and laboratory data (26,510 data points for blood cell counts/serum values in 25 days around transplantation). We detected CHrelated mutations in 152 patients (33.3%). Since many patients (n=54) harbored multiple CH mutations in one or more genes, we applied a non-negative matrix factorization (NMF) clustering algorithm to identify genes that are commonly co-mutated in an unbiased approach. Patients with CH were assigned to one of three clusters (C1-C3) and compared to patients without CH (C0) in a gene specific manner. To study the dynamics of blood cell regeneration following ASCT, we developed a time-dependent linear mixed effect model to validate differences in blood cell count trajectories amongst different clusters. The results demonstrated that C2, composed of patients with DNMT3A and PPM1D single and co-mutated CH, correlated with reduced stem cell yields and delayed platelet count recovery following ASCT. Also, the benefit of maintenance therapy was particularly strong in C2 patients. Taken together, these data indicate an impaired regenerative potential of hematopoietic stem cell grafts harboring CH with DNMT3A and PPM1D mutations.